Artificial pancreas: The bridge to a cure for type 1 diabetes

European Diabetes Nursing

Volumn 9, Issue 2, 2012, Pages 56-60

  Thabit, H ^a   Hovorka, R ^a   Evans, M ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Artificial pancreas; Closed loop insulin delivery; Type 1 diabetes mellitus

Indexed keywords

EID: 84867134201     PISSN: 15517853     EISSN: 15517861     Source Type: Journal    
DOI: 10.1002/edn.207     Document Type: Review

References (42)

1. Group DP. Incidence and trends of childhood type 1 diabetes worldwide 1990-1999. Diabet Med 2006;23:857-66.
2. Bruno G, Novelli G, Panero F, et al. The incidence of type 1 diabetes is increasing in both children and young adults in Northern Italy: 1984-2004 temporal trends. Diabetologia 2009;52:2531-5.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The DCCT Research Group. N Engl J Med 1993;329:977-86.
4. Unger J, Parkin C. Hypoglycemia in insulin-treated diabetes: a case for increased vigilance. Postgrad Med 2011;123:81-91.
5. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76.
6. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011;7:385-95.
7. Klonoff DC. Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care 2005;28:1231-9.
8. Lin EH, Katon W, Von Korff M, et al. Relationship of depression and diabetes self-care, medication adherence, and preventive care. Diabetes Care 2004;27:2154-60.
9. Feldman B, Brazg R, Schwartz S, et al. A continuous glucose sensor based on wired enzyme technology - results from a 3-day trial in patients with type 1 diabetes. Diabetes Technol Ther 2003;5:769-79.
10. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self monitoring of blood glucose: meta-analysis of randomised controlled trials using individual patient data. BMJ 2011;343:d3805.
11. Pickup J, Keen H. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes. Diabetes Care 2002;25:593-8.
12. Bergenstal RM, Tamborlane WV, Ahmann A, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010;363:311-20.
13. Choudhary P, Shin J, Wang Y, et al. Insulin pump therapy with automated insulin suspension in response to hypoglycemia: reduction in nocturnal hypoglycemia in those at greatest risk. Diabetes Care 2011;34:2023-5.
14. Magni L, Raimondo DM, Bossi L, et al. Model predictive control of type 1 diabetes: an in silico trial. J Diabetes Sci Technol 2007;1:804-12.
15. Hovorka R, Canonico V, Chassin LJ, et al. Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiol Meas 2004;25:905-20.
16. El-Khatib FH, Russell SJ, Nathan DM, et al. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med 2010;2:27ra27.
17. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375(9716):743-51.
18. Marchetti G, Barolo M, Jovanovic L, et al. An improved PID switching control strategy for type 1 diabetes. IEEE Trans Biomed Eng 2008;55(3):857-65.
19. Steil GM, Rebrin K, Darwin C, et al. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-50.
20. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-7.
21. Kovatchev BP, Breton M, Man CD, et al. In silico preclinical trials: a proof of concept in closed-loop control of type 1 diabetes. J Diabetes Sci Technol 2009;3:44-55.
22. Wilinska ME, Blaha J, Chassin LJ, et al. Evaluating glycemic control algorithms by computer simulations. Diabetes Technol Ther 2011;13:713-22.
23. Klonoff DC, Cobelli C, Kovatchev B, et al. Progress in development of an artificial pancreas. J Diabetes Sci Technol 2009;3:1002-4.
24. Dassau E, Zisser H, Palerm CC, et al. Modular artificial beta-cell system: a prototype for clinical research. J Diabetes Sci Technol 2008;2:863-72.
25. Steil GM, Palerm CC, Kurtz N, et al. The effect of insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402-8.
26. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:d1855.
27. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther 2009;11(Suppl 1):S113-9.
28. Danne T, Kordonouri O, Holder M, et al. Prevention of hypoglycemia by using Low Glucose Suspend function in sensor-augmented pump therapy. Diabetes Technol Ther 2011;13:1129-34.
29. Buckingham B, Chase HP, Dassau E, et al. Prevention of nocturnal hypoglycemia using predictive alarm algorithms and insulin pump suspension. Diabetes Care 2010;33:1013-7.
30. Elleri D, Allen JM, Nodale M, et al. Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with type 1 diabetes. Diabet Med 2010;27:480-4.
31. Cengiz E, Swan KL, Tamborlane WV, et al. Is an automatic pump suspension feature safe for children with type 1 diabetes? An exploratory analysis with a closed-loop system. Diabetes Technol Ther 2009;11:207-10.
32. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991;90:450-9.
33. Elleri D, Allen JM, Kumareswaran K, et al. Day-and-night closed loop (CL) glucose control in adolescents with type 1 diabetes (T1D). Diabetes 2011;60(Suppl 1):A41.
34. Weinzimer SA, Steil GM, Swan KL, et al. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-9.
35. Steil GM, Rebrin K. Closed-loop insulin delivery - what lies between where we are and where we are going? Expert Opin Drug Deliv 2005;2:353-62.
36. Garg SK, Voelmle M, Gottlieb PA. Time lag characterization of two continuous glucose monitoring systems. Diabetes Res Clin Pract 2010;87:348-53.
37. Weinstein RL, Schwartz SL, Brazg RL, et al. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care 2007;30:1125-30.
38. McGarraugh G, Bergenstal R. Detection of hypoglycemia with continuous interstitial and traditional blood glucose monitoring using the FreeStyle Navigator Continuous Glucose Monitoring System. Diabetes Technol Ther 2009;11:145-50.
39. Ellingsen C, Dassau E, Zisser H, et al. Safety constraints in an artificial pancreatic beta cell: an implementation of model predictive control with insulin on board. J Diabetes Sci Technol 2009;3:536-44.
40. Heinemann L. Variability of insulin absorption and insulin action. Diabetes Technol Ther 2002;4:673-82.
41. Turner BC, Jenkins E, Kerr D, et al. The effect of evening alcohol consumption on next-morning glucose control in type 1 diabetes. Diabetes Care 2001;24:1888-93.
42. Carroll MF, Schade DS. The dawn phenomenon revisited: implications for diabetes therapy. Endocr Pract 2005;11:55-64.